Rezafungin acetate - Generic Drug Details

What are the generic sources for rezafungin acetate and what is the scope of freedom to operate?

Rezafungin acetate is the generic ingredient in one branded drug marketed by Mundipharma and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rezafungin acetate has one hundred and six patent family members in twenty-eight countries.

One supplier is listed for this compound.

Summary for rezafungin acetate

International Patents:	106
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	14
Clinical Trials:	2
DailyMed Link:	rezafungin acetate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for rezafungin acetate

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for rezafungin acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mundipharma Research Limited	PHASE2
Mundipharma Research Limited	Phase 1

See all rezafungin acetate clinical trials

Pharmacology for rezafungin acetate

Drug Class

Echinocandin Antifungal

Anatomical Therapeutic Chemical (ATC) Classes for rezafungin acetate

J02AX	Other antimycotics for systemic use
J02A	ANTIMYCOTICS FOR SYSTEMIC USE
J02	ANTIMYCOTICS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for rezafungin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	11,654,196		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	9,526,835		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	8,722,619		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	11,819,533		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	11,712,459		Y

International Patents for rezafungin acetate

Country	Patent Number	Title	Estimated Expiration
Australia	2013235512
Australia	2017201758
Australia	2019201072
Australia	2020256337
Canada	2867132
China	104507309

Supplementary Protection Certificates for rezafungin acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2680873	2024C/527	Belgium		PRODUCT NAME: REZAFUNGINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER REZAFUNGINEACETAAT; AUTHORISATION NUMBER AND DATE: EU/1/23/1775 20231222
2680873	CA 2024 00025	Denmark		PRODUCT NAME: REZAFUNGIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER REZAFUNGINACETAT; REG. NO/DATE: EU/1/23/1775 20231222
2680873	24C1027	France		PRODUCT NAME: REZAFUNGINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE REZAFUNGINE, EN PARTICULIER ACETATE DE REZAFUNGINE; REGISTRATION NO/DATE: EU/1/23/1775 20231222
2680873	PA2024520	Lithuania		PRODUCT NAME: REZAFUNGINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC REZAFUNGINO ACETATAS; REGISTRATION NO/DATE: EU/1/23/1775 20231222
2680873	CR 2024 00025	Denmark		PRODUCT NAME: REZAFUNGIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER REZAFUNGINACETAT; REG. NO/DATE: EU/1/23/1775 20231222
2680873	122024000037	Germany		PRODUCT NAME: REZAFUNGIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE REZAFUNGINACETAT; REGISTRATION NO/DATE: EU/1/23/1775 20231222

Last updated: July 5, 2026

Rezafungin acetate market dynamics and financial trajectory: pricing, adoption, payer pressure, and IP-driven launch risks

Rezafungin acetate (Rezzayo) is positioned as a weekly, intravenous treatment for candidemia and invasive candidiasis, competing against echinocandins and, on trajectory, testing against oral step-down and hospital formulary constraints. Commercial upside hinges on: (1) sustained US and ex-US hospital uptake in high-acuity bloodstream infection units, (2) payer acceptance of a higher-priced, longer-dosing-interval echinocandin, and (3) whether manufacturer execution supports repeat-use demand beyond initial trial-to-real-world conversion. Financial trajectory is driven by the timing of guideline penetration, hospital contracting cycles, and how quickly rezafungin can become a default echinocandin within stewardship protocols versus seasonal “first-line” rotations.

No complete, decision-grade market sizing dataset is provided here, so the analysis below focuses on IP and competitive dynamics that govern near-to-medium term revenue trajectory and valuation risk: exclusivity timing, patent/settlement overhang, biosimilar/generic threat framing for an IV small molecule, and regulatory and formulary adoption factors that translate directly into sales ramp speed.

---

How is rezafungin acetate performing commercially and what drives its revenue ramp?

Short answer: Revenue ramp is expected to track hospital formulary adoption and contract pricing more than incremental clinical differentiation, because rezafungin is an echinocandin administered in hospital settings where pharmacy and therapeutics committees control utilization.

What determines conversion from “approved” to “used”

Rezafungin is used in inpatient and ICU settings for candidemia/invasive candidiasis. That creates four commercial drivers:

1. Payer contracting cadence

   • US commercial and Medicare Advantage plans typically require discounting or utilization management aligned to hospital formularies and drug acquisition costs.
   • For high-cost oncology-style pricing pressure is typical, but for antimicrobials the pressure is expressed through restricted formulary placement and prior authorization.

2. Hospital operational fit

   • Weekly dosing can reduce nursing administration time, decrease IV line access events, and improve regimen adherence across multiple days.
   • The financial translation is strongest in hospitals that manage echinocandin protocols across wards, not only ICU.

3. Stewardship protocols

   • Where hospitals run standardized “empiric echinocandin” pathways, rezafungin’s differentiation must win committee preference, not just clinician preference.
   • If stewardship favors rotating echinocandins to manage acquisition costs, rezafungin’s long-interval dosing can still matter, but contract terms decide outcomes.

4. Competitive substitution dynamics

   • Practitioners compare on “total course cost” and on practical continuity: if a patient stabilizes quickly, step-down may shift economics.

Key competitive baseline

Rezafungin’s competitive set includes echinocandins used for candidemia: caspofungin, micafungin, and anidulafungin. These products have entrenched procurement channels, established formularies, and mature substitution habits. Rezafungin’s ramp depends on taking share inside those existing procurement rules, not on creating entirely new treatment patterns.

---

What market dynamics shape rezafungin acetate pricing and payer coverage?

Short answer: Pricing and access hinge on hospital contracting, course-of-therapy economics, and whether payer coverage restrictions are limited to “restricted use” rather than near-complete denial.

Where payer leverage shows up

• Inpatient formularies: Pharmacy and therapeutics committees and wholesaler contract terms determine which echinocandin gets “preferred” status.
• Coverage policies: Plans may require documentation of candidemia/invasive candidiasis confirmation or restriction to particular severity markers.
• Site of care: Rezafungin is IV inpatient. That means utilization is mainly controlled by hospital supply chain decisions rather than home infusion economics.

How weekly dosing changes the negotiation

Weekly administration can reduce operational costs (nursing time, infusion center utilization, line management). Those savings can support higher net prices if hospitals can quantify reduced costs, but most contract negotiations will still net to:

• acquisition cost per week
• expected length of therapy
• formulary status across competing echinocandins

Adoption risk signals to monitor

• Formulary exclusion in large ID hospitals slows share capture.
• Stewardship resistance reduces uptake even after positive clinical outcomes.
• Protocol mismatches (for example, when hospitals keep a default echinocandin that is already deeply discounted) can flatten ramp.

---

When does rezafungin lose exclusivity and how does that affect long-term revenue?

Short answer: Long-term revenue is driven by the last-to-expire exclusivity and patent estate rather than by initial FDA approval timing. For a specialty IV antibiotic, post-launch revenue depends on preventing generic entry and competing product cannibalization until late-stage patent cliffs.

Exclusivity and patent-driven revenue cliffs

For a small-molecule IV drug, the practical threat is:

• generic entry once Orange Book-listed exclusivities/patents expire and barriers (for example, patent reach-through) are cleared
• authorized or off-patent competitor substitution even without a full generic launch

What matters for financial modeling

• the last FDA exclusivity date (if any) tied to the approved indication
• the last US patent expiration date in the Orange Book for listed claims
• whether there are formulation or method-of-use patents that survive generic design-arounds

Because this prompt does not include rezafungin’s Orange Book listing dates or specific patent numbers, a complete exclusivity calendar cannot be stated with decision-grade precision here.

---

What Orange Book status does rezafungin acetate have and what patents protect it?

Short answer: Orange Book status and the identity of protecting patents determine generic Paragraph IV risk, but no Orange Book listing content is included in the prompt, preventing a reliable, numbers-and-expiration-based mapping here.

Patent estate categories that control generic feasibility

Rezafungin’s patent estate, if typical for a branded IV specialty drug, likely includes:

• drug substance claims tied to rezafungin acetate composition and stereochemical/chemical definitions
• drug product claims (formulation, concentration ranges, stabilizers)
• method-of-use claims (indications and/or dosing regimens)

Generic feasibility depends on whether challengers can “carve out” claims via labeling changes or whether composition claims block development.

---

Are there Paragraph IV challenges or generic entry risks for rezafungin acetate?

Short answer: Generic entry risk is governed by whether there are Paragraph IV filings tied to Orange Book patents and by the scope of protecting claims. No specific filing data is provided in the prompt.

How Paragraph IV filings typically translate into revenue impact

A generic launch timeline changes company financials only when:

• a Paragraph IV challenger wins or settles
• the labeling triggers carve-outs that preserve branded use
• the brand retains differentiated dosing or stewardship positioning

For a weekly dosing regimen, even if a generic reaches approval, prescriber preference may persist if:

• the generic label aligns with “weekly” administration
• contracts still favor the originator

Without Orange Book and FDA litigation data in the prompt, a decision-grade risk assessment cannot be produced.

---

Which companies compete with rezafungin acetate in hospitals and how does that affect market share?

Short answer: Competition is principally echinocandins, with share won through formulary preference and contract pricing. The most relevant commercial competitors are established branded echinocandins and their generic/authorized supply chains.

Competitive substitution map (mechanism class)

• Caspofungin (echinocandin)
• Micafungin (echinocandin)
• Anidulafungin (echinocandin)

How competition affects financial trajectory

• If rezafungin achieves preferred formulary placement, share gains can be durable.
• If it is placed only on restricted use, volume may remain below the company’s ramp model even if clinical adoption is strong.

The financial trajectory therefore depends on:

• whether hospitals standardize on a single echinocandin or maintain a cost-based rotation
• whether rezafungin’s weekly dosing creates measurable operational and course-of-therapy savings

---

How do rezafungin acetate manufacturing and supply constraints influence sales?

Short answer: For IV hospital drugs, supply reliability is a direct sales variable: stockouts convert to competitor switching that can be slow to reverse due to contract and protocol inertia.

Supply chain dynamics

• wholesaler allocation and lead times affect whether hospitals maintain preferred status
• if shortages occur, hospitals often substitute to pre-contracted alternatives
• replenishment after a shortage rarely restores shares to prior levels quickly without new contracting

This can materially shift the revenue trajectory during early launch and any mid-cycle demand surge.

---

What regulatory milestones and label scope changes influence uptake?

Short answer: Uptake is tied to label breadth and whether the approved indication covers real-world patient segments that stewardship treats. A narrow label reduces pool size, while broader label allows easier protocol placement.

Regulatory scope as a commercial lever

• hospitals build order sets aligned to labeling and clinical pathways
• wider label and dosing flexibility support stronger integration into empiric protocols

No label-expansion timelines are included in the prompt, so they cannot be quantified here.

---

What is the biosimilar or biologics risk for rezafungin acetate?

Short answer: Rezafungin acetate is a small-molecule drug, so biosimilar risk is not applicable in the same way as it is for biologics. The relevant risk is generic substitution and authorized competitors.

---

How strong is the patent estate for rezafungin acetate and what does that imply for valuation?

Short answer: The patent estate’s strength is the valuation anchor because it governs duration of branded pricing power and delays generic/cannibalization. Without Orange Book patent numbers and expiration dates in the prompt, a quantified “strength” score cannot be built.

What an investor model must incorporate

• last patent expiry date (US)
• number of listed patents and whether multiple claims are likely to survive design-around
• likelihood of Paragraph IV challenges and probability of settlement vs litigation outcomes
• any formulation or dosing-regimen claims that preserve differentiation after generic entry

---

Key takeaways

• Rezafungin acetate’s financial trajectory is driven by formulary adoption and hospital contracting more than by minor clinical incremental arguments within the echinocandin class.
• Weekly inpatient dosing can improve operational economics, but payer and hospital discounting still determine net revenue.
• Medium-to-long term revenue risk is primarily patent-expiration and generic entry timing, not biosimilar dynamics.
• The biggest controllable commercial risk is supply reliability; stockouts can lock out share via protocol inertia.
• A decision-grade exclusivity calendar and Paragraph IV risk ranking require Orange Book listings and litigation records, which are not included in the prompt.

---

FAQs

1. What types of hospital formularies most affect echinocandin uptake for rezafungin acetate?
2. How does weekly IV dosing change pharmacy budget impact versus daily echinocandins?
3. What endpoints in candidemia guidance drive switching decisions among echinocandins?
4. How do inpatient contract cycles affect speed of market share capture for newly launched IV antibiotics?
5. What are the main drivers of generic substitution speed for small-molecule IV antimicrobials after Orange Book expiration?

---

References

No sources were provided in the prompt to cite.